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Abstract
Background: In West Africa, envenoming by saw-scaled or carpet vipers (Echis ocellatus) causes great morbidity and
mortality, but there is a crisis in supply of effective and affordable antivenom (ISRCTN01257358).
Methods: In a randomised, double-blind, controlled, non-inferiority trial, ‘‘EchiTAb Plus-ICP’’ (ET-Plus) equine antivenom
made by Instituto Clodomiro Picado was compared to ‘‘EchiTAb G’’ (ET-G) ovine antivenom made by MicroPharm, which is
the standard of care in Nigeria and was developed from the original EchiTAb-Fab introduced in 1998. Both are caprylic acid
purified whole IgG antivenoms. ET-G is monospecific for Echis ocellatus antivenom (initial dose 1 vial) and ET-Plus is
polyspecific for E. ocellatus, Naja nigricollis and Bitis arietans (initial dose 3 vials). Both had been screened by pre-clinical and
preliminary clinical dose-finding and safety studies. Patients who presented with incoagulable blood, indicative of systemic
envenoming by E. ocellatus, were recruited in Kaltungo, north-eastern Nigeria. Those eligible and consenting were randomly
allocated with equal probability to receive ET-Plus or ET-G. The primary outcome was permanent restoration of blood
coagulability 6 hours after the start of treatment, assessed by a simple whole blood clotting test repeated 6, 12, 18, 24 and
48 hr after treatment. Secondary (safety) outcomes were the incidences of anaphylactic, pyrogenic and late serum sickness-
type antivenom reactions.
Findings: Initial doses permanently restored blood coagulability at 6 hours in 161/194 (83.0%) of ET-Plus and 156/206
(75.7%) of ET-G treated patients (Relative Risk [RR] 1.10 one-sided 95% CI lower limit 1.01; P=0.05). ET-Plus caused early
reactions on more occasions than did ET-G [50/194 (25.8%) and 39/206 (18.9%) respectively RR (1.36 one-sided 95% CI 1.86
upper limit; P=0.06). These reactions were classified as severe in 21 (10.8%) and 11 (5.3%) of patients, respectively.
Conclusion: At these doses, ET-Plus was slightly more effective but ET-G was slightly safer. Both are recommended for
treating E. ocellatus envenoming in Nigeria.
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Introduction
Bites by saw-scaled or carpet vipers (Echis ocellatus) are frequent
in the savanna region of West Africa, where agricultural workers
and their children are at greatest risk [1–6]. Systemic haemor-
rhage, consumption coagulopathy, shock and debilitating local
tissue necrosis may ensue [6]. Fatalities result from haemostatic
failure susceptibility to which is conveniently detected and
monitored by the 20 minute whole blood clotting test [6] which
correlates with a plasma fibrinogen concentration of about 0.5 g/l [7]
and has been used in several previous antivenom trials [3–6,8–17].
In Nigeria, where untreated case fatality exceeds 10–20%, E.
ocellatus causes hundreds of deaths each year [1,18,19]. In recent
years, antivenom has become scarce, costly and inaccessible to
www.plosntds.org 1 July 2010 | Volume 4 | Issue 7 | e767most patients [18,20–23]. This provides an entre ´e for unscrupu-
lous marketing of geographically-inappropriate products that can
prove clinically disastrous [3,24,25]. Improving the treatment of
snake bite victims in Nigeria demands solutions to economic,
logistical, marketing, distribution and storage problems associated
with antivenom supply and provision of better training for
medical personnel to optimize antivenom use [26–28]. The
development of safe, effective and affordable antivenoms is a
priority [28]. In the 1990s, the Federal Ministry of Health in
Nigeria (FMHN) supported the development of a new ovine Fab
monospecific antivenom raised against Nigerian E. ocellatus venom
(EchiTAb-Fab antivenom) by MicroPharm, UK. This antivenom
was tested [8,29], registered by the Nigerian National Agency for
Food and Drug Administration and Control (NAFDAC) and used
in Nigeria from 1998–2000. However, its use, like that of
CroFabH in the United States [30], was complicated by recurrent
envenoming [31] attributable to rapid clearance of the Fab
fragments [8]. To overcome this problem, it was replaced by a
caprylic acid-refined, whole IgG antivenom (EchiTAb-G) (ET-G)
with the same specificity. This proved clinically effective during
compassionate clinical release in Nigeria, becoming the standard
of care. During pre-trial use at Kaltungo, in early 2005, 146 of
182 (80%; 95% confidence interval 74%–85%) patients enven-
omed by E. ocellatus showed permanent restoration of blood
coagulability 6 hours after an initial dose of 1 vial of ET-G
(unpublished data). This antivenom was registered by NAFDAC
(registration number A6-0078). Recently, a new equine whole
IgG antivenom (EchiTAb-Plus-ICP) (ET-Plus) was prepared by
Instituto Clodomiro Picado, Costa Rica, also refined using
caprylic acid [32–34]. It was raised against venoms of E. ocellatus,
puff adder (Bitis arietans) and black-necked spitting cobra (Naja
nigricollis), the taxa of greatest medical importance in Nigeria. Pre-
clinical (rodent ED50 assay) and preliminary clinical dose-finding
and safety studies suggested that initial doses of 1 vial of ET-G
and 3 vials of ET-Plus might cure the coagulopathy in at least two
thirds of patients [35].
A natural progression of this work was a larger Phase III head-
to-head comparison of both antivenoms in a non-inferiority
design, since ET-G was the established standard of care. Since the
untreated case fatality rate for E. ocellatus envenoming, inferred
from results of treatment with inappropriate non-specific anti-
venoms, has been reported as 12.1% (95% CI: 6.3–22.1%) [3] and
15.8% (95% CI: 10.4–23.4%) [1], it was considered unethical to
include a placebo comparator arm. In this paper, we compare the
effectiveness in correcting coagulopathy and safety of ET-Plus with
those of ET-G (standard treatment) for envenoming by E. ocellatus,
in a randomised controlled double-blind non-inferiority trial.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Objectives
In the face of the current crisis in antivenom availability in
Nigeria, our main aim was to evaluate effective and acceptably
safe treatments for E. ocellatus envenoming in a randomised
controlled double-blind non-inferiority trial, comparing ET-Plus, a
new antivenom, with ET-G, an antivenom of established
effectiveness which has been the standard for care in Nigeria
since 2005.
Participants
Patient eligibility. All patients presenting to Kaltungo
General Hospital, Gombe State, Nigeria with a history of snake
bite were assessed for their eligibility.
Inclusions - all patients of any age provided that:
1) they had incoagulable blood as defined by the 20 minute
whole blood clotting test (20WBCT) [6,7] indicative of
systemic envenoming by E. ocellatus in this geographical area
[1,6,8,9,11].
2) they had been bitten within the previous 72 hours
3) they or their relatives gave informed consent to admission,
treatment and investigation
Exclusions:
1) patients who had already received antivenom for their
present snake bite
2) pregnant women (as required by the local ethics committee)
3) patients whose signs and symptoms of intracerebral
haemorrhage (coma, and/or lateralising neurological signs)
demanded immediate treatment with an antivenom of
established clinical effectiveness (see below).
4) patients with a severe unrelated medical condition such as
advanced AIDS or tuberculosis (as required by the local
ethics committee)
Ineligible patients were treated, outside the trial, with a large
initial dose of ET-G antivenom, currently standard of care in
Nigeria, or South African Vaccine Producers (SAVP) Echis
antivenom [6,9].
Medical history and results of physical examination were
recorded on standard forms on admission and at least daily
thereafter until discharge.
Interventions
Antivenom. Both antivenoms had passed their manufac-
turers’standard tests for neutralising potency, purity, lack of
pyrogenicity (endotoxin levels equal to or less than 6 eu/ml)
aggregate content (3.060.4% by gel filtration chromatography),
high molecular mass components (molecular masses above that of
Author Summary
Snake bite threatens millions of poor rural folk throughout
Africa. In Nigeria, as in many countries of sub-Saharan
Africa, it takes a terrible toll on human life and limb. Over
the years, the news for those exposed to snake bite has
been generally bad: withdrawal of antivenom manufac-
turers, increasing cost and, most recently, the marketing of
ineffective or fake antivenoms in the region. Our paper
reports encouraging results achieved by two antivenoms
created as a direct consequence of the present crisis in
antivenom supply for Africa. They have been assessed in
the most powerful trial ever attempted in this field. The
trial showed that in people with non-clotting blood
following carpet viper bite, the commonest cause of snake
bite morbidity and mortality in the West African savannah,
administration of the antivenoms- EchiTAb G and EchiTAb
Plus-ICP led to permanent restoration of blood clotting in
76% and 83% of the patients within 6 hours, respectively.
Generally mild early adverse reactions were recorded in
19% and 26%, respectively. Both antivenoms proved
effective and acceptably safe and can be recommended
for treating carpet viper envenoming in Nigeria.
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Plus 40 mg/ml, ET-G, 37 mg/ml), lack of abnormal toxicity,
sterility, pH (ET-Plus 6.83, ET-G 5.8-6.2) and other recommended
tests [33–35].The batches ofantivenom used inthestudy were: ET-
Plus 3710204LQ (exp. February 2007) and 4260308PALQ (exp.
March 2011); ET-G EoG00068 (exp. January 2007), EoG00077
(exp. May 2007), EoG00084 (exp. July 2007).
The initial doses of antivenom chosen for this study were
derived by pre-clinical and preliminary clinical dose-finding/
safety studies as follows [35]. Median effective doses (ED50)o f
candidate antivenoms, obtained by using standard neutralisation
assays in rodents, were the basis for calculating doses capable of
neutralising the maximum amount of venom that could be milked
from captive E. ocellatus. These doses were tested clinically in
v o l u n t e e rp a t i e n t se n v e n o m e db yE. ocellatus in a modified 3+3
dose escalation protocol. The resulting ‘‘minimum effective safe
doses’’ were 3 vials of ET-Plus and 1 vial of ET-G [35].
Antivenoms were administered intravenously at a rate of
approximately 2 ml/minute. The initial dose was repeated at 6
hourly intervals until blood coagulability, assessed by 20WBCT,
was restored permanently or until the case was deemed a
‘‘treatment failure’’, defined as failure to achieve permanent
restoration of blood coagulability within 24 hours of the first
dose. In such cases, ‘‘rescue treatment’’ was given: 2 vials of ET-
G (currently the standard of care) or, when available, SAVP Echis
antivenom [6,9]. To exclude recurrent envenoming, 20WBCT
was repeated 6 hourly for 48 hours after blood coagulability had
been restored and daily thereafter up to 96 hours after the start of
antivenom treatment to cover the longest reported delay in
recurrence [6,8].
Other treatment. Pain was treated with oral paracetamol
(adult 1 g 6 hourly) orcodeinephosphate (30 mg).Freshcompatible
HIV, HBV, HCV-negative whole blood (screened through
Columbia University’s International Centre for AIDS Care &
Treatment Program - ICAP) was transfused if the haematocrit fell
below 20%. Envenomed limbs were nursed in the most comfortable
position. A booster dose of tetanus toxoid was given to every patient.
If local necrosis developed, the affected area was surgically de ´brided
and broad-spectrum antimicrobial cover (flucloxacillin, gentamicin
and metronidazole) was started immediately.
Outcomes
Primary outcome. The primary outcome was permanent
restoration of blood coagulability, judged by 20WBCT at 6 hours
after initiation of antivenom treatment. ‘‘Permanent’’ implied
restoration after which there was no (further) recurrence of blood
incoagulability. This was assessed by repeating the 20WBCT 6,
12, 18, 24 and 48 hr after the initial dose of antivenom.
Restoration of blood coagulability, assessed by 20WBCT, was
taken as evidence of the effectiveness of the antivenom in
neutralising anti-haemostatic effects of E. ocellatus venom. Persis-
tence of incoagulable blood six hours after the first or subsequent
doses of antivenom was the indication for repeating the initial dose
of antivenom as in previous studies [6,8,9,11].
20WBCT method. 2ml of venous blood was taken into a
2666 mm new, clean, dry glass test tube, left upright and
undisturbed for 20 minutes at ambient temperature and then
tipped once. If the blood poured out in liquid form, the result was
termed ‘‘unclotted’’; otherwise, the result was termed ‘‘clotted’’. If
there was any doubt about the result, the test was repeated
immediately, using as control blood from a healthy person, usually
the patient’s relative [1,6,7,8,9,11].
Secondary (safety) outcomes. Secondary (safety) outcomes
included the incidences of (1) early anaphylactic-like, (2) pyrogenic,
and (3) late serum sickness type antivenom reactions. Patients were
observed closely by the clinician for any symptoms or signs of early
antivenom reactions during and for a period of 4 hours after
antivenom administration.
Early reactions were classified as:
1) Anaphylactic-like
i. mild - pruritus and/or urticaria only
ii. severe - gastrointestinal symptoms (vomiting, diarrhoea,
colicky abdominal pain), bronchospasm, or fall in systolic
blood pressure below 90 mmHg.
Anaphylactic-like reactions were treated by temporarily
stopping antivenom injection and giving 0.1% adrenaline
by intramuscular injection (adult dose 0.5–1 ml; children
0.01 ml/kg body weight), followed by chlorphenamine
maleate by slow intravenous injection (adult dose 10 mg;
children 0.2 mg/kg body weight) and hydrocortisone hemi-
succinate by slow intravenous injection (adult dose 100 mg;
children 2 mg/kg body weight). After the symptoms of the
reaction had subsided, administration of the full dose of
antivenom was completed.
2) Pyrogenic- increase in oral temperature to 38u or above with
or without rigors. They were treated by temporarily stopping
antivenom injection and using physical cooling (tepid
sponging and fanning). After the fever and other symptoms
had subsided, administration of the full dose of antivenom
was completed.
3) Late serum sickness-type reactions. Patients were encouraged
to return to hospital 2 weeks after the bite to allow assessment
of symptoms and signs of serum sickness which was treated
with chlorphenamine or prednisolone tablets.
Ancillary clinical outcomes. On admission, history and
physical examination were recorded on standard proformas.
Sites of external spontaneous systemic bleeding (gums, nose etc.)
were examined frequently until the bleeding had ceased
permanently. Subsequently, patients were questioned about
new symptoms and were examined at regular intervals, at
least twice daily, with special emphasis on vital signs, evidence of
recurrent envenoming and evolution of local envenoming.
Duration of hospital stay was measured to the nearest day.
Patients were discharged from hospital by the clinician who was
masked to the particular antivenom that they had received.
Haematocrit (packed cell volume - PCV) was checked at
discharge.
Patients were asked to attend for follow-up assessment 2 weeks
after the bite for physical examination with particular attention to
local envenoming and serum sickness (see above).
Sample size
The trial was designed to demonstrate non-inferiority of ET-
Plus compared to ET-G. A 10% non-inferiority margin was
deemed acceptable (i.e. we stipulated that at least 70% of ET-Plus
patients must have permanent restoration of blood coagulability at
6 hours for it to be deemed non-inferior to ET-G). A sample size
of 198 in each group provides 80% power to detect this non-
inferiority margin difference of 10%, at a 5% one-sided
significance level. It was anticipated that there would be no losses
to follow up.
Randomisation and masking
Patients were screened for eligibility and enrolled by one of the
study clinicians who then contacted the hospital pharmacist
Trial of Antivenoms in Carpet Viper Envenoming
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Patients were allocated to receive either ET-Plus or ET-G with
equal probability (allocation ratio 1:1) using simple randomisation.
The random number sequence was generated using a table of
random numbers. Treatment allocations were concealed by using
sequentially numbered opaque sealed envelopes held by the
hospital pharmacist who was otherwise independent of the study.
He provided the masked antivenoms after reconstituting them to
total volumes of 40 mls with sterile water for injection in an
unmarked syringe. Diluted in this way, ET-Plus 3:4, ET-G 1:4,
both antivenoms appeared as identical colourless solutions. The
patient, ward staff and treating clinicians, who also assessed the
outcome, were thus masked to the identity of the particular
antivenom used.
Statistical methods
Patients were analysed in the groups to which they were
assigned regardless of deviation from the protocol or treatment
received (intention-to-treat population). Baseline demographic
factors and clinical characteristics were summarised using counts
(percentages) for categorical variables, mean (standard deviation
[SD]) for normally distributed continuous variables, or median
(interquartile [IQR] or entire range) for other continuous
variables.
To determine the magnitude and direction of the treatment
effects for dichotomous outcomes, relative risks and one-sided 95%
confidence intervals were calculated; the lower limit was provided
when comparing antivenom effectiveness (where an increase in
positive events is desirable) whereas the upper limit was provided
when comparing safety (where a decrease in negative events is
desirable). Continuous outcomes were checked for normality and
the treatment groups were compared using either the t test (for
normally distributed data) or the Mann Whitney-U test (for non-
normally distributed data). Treatment effects were presented as a
corresponding difference in means or medians (plus one-sided
95% confidence intervals).
Ethics
ET-G and ET-Plus were given limited registration for clinical
trials by NAFDAC. The trial was sanctioned by NAFDAC and the
Gombe State Medical Research Ethics Committee. Written
informed consent (in English or Hausa, the common language of
this region) was obtained from the patients after they had read the
information sheet and discussed it with medical staff. Oral
explanations in Tangale or Fulani were also available.
Results
Recruitment and participant flow
The trial was conducted during the period 2005–2007, but
recruitment was possible for only 9 months, because of staffing
problems and delayed importation and authorisation by
NAFDAC of the second consignment of ET-Plus antivenom.
During this time, 1102 patients presented to the hospital with a
history of snake bite and were assessed for eligibility (Figure 1).
Among 646 patients who were ineligible because their blood
was coagulable, 74 had been bitten by snake species other than
E. ocellatus [night adders (Causus maculatus), burrowing asps
(Atractaspis dahomeyensis and A. watsoni)a n dc o b r a s( Naja nigricollis)
identified by examination of the dead snakes brought by these
patients] and 572 showed only local or no envenoming. Among
456 with incoagulable blood (20WBCT), indicating systemic
envenoming by E. ocellatus, 26 refused to join the study, 4 were
excluded because of difficult venous access and 26 were
ineligible for the following reasons as per protocol: pregnancy
(10), antivenom treatment for their present bite (2), evidence of
coma/cerebral haemorrhage on admission (4), severe underly-
ing illness (HIV/AIDS) (2), bitten more than 72 hr previously
(8). Of 400 recruited to the study, 68 were children under the
age of 14.
Baseline characteristics
One hundred and ninety four patients allocated ET-Plus proved
to be broadly similar to 206 allocated ET-G in their demographic
and clinical characteristics, including age, height and weight,
proportion who brought the dead snake (Echis ocellatus) that had
bitten them, sex, proportion of children, delay between bite and
admission, site of bite, severity of local envenoming and incidence
of spontaneous systemic bleeding (Table 1).
Outcomes
Primary end point. Coagulopathy response (judged by
20WBCT) - blood coagulability was permanently restored within
six hours of the initial dose in 161 of 194 (83.0%) patients given
three vials of ET-Plus and in 156 of the 206 (75.7%) patients given
one vial of ET-G (Table 2; RR 1.10 one-sided 95% CI lower limit
1.01; P=0.05).
Recurrent blood incoagulability after initial restoration of
coagulability occurred in 24 cases, 7 after ET-Plus and 17 after
ET-G (Table 3). As per protocol, rescue treatment was given to
patients whose blood was incoagulable 24 hr after starting
antivenom treatment (Table 3). In all 400 patients, coagulopathy
had resolved permanently within 60 hours of starting antivenom
and there were no fatalities (Table 3).
Secondary (Safety) end points.
1) Anaphylactic-like reactions
ET-Plus caused one or more reactions on more occasions
than ET-G [50/194 (25.8%) and 39/206 (18.9%) respectively
[RR 1.36 one-sided 95% CI upper limit 1.86; P=0.06].
Among the patients who reacted to ET-Plus and ET-G, 21
(10.8%) and 11 (5.3%) respectively experienced broncho-
spasm or gastrointestinal symptoms defined as ‘‘severe’’ [RR
2.03 one-sided 95% upper limit 3.66; P=0.03] (Table 3).
2) Pyrogenic reactions
No pyrogenic reactions were observed.
3) Late serum sickness-type reactions
Only 107 patients (26.8%) attended for follow-up. Of the 49
of them who had received ET-Plus, 5 had late reactions and
of the 58 who had received ET-G, 3 had late reactions.
Ancillary clinical outcomes. Spontaneous systemic bleeding
was detected in 71/194 (36.6%) and 79/206 (38.3%) of patients in
the ET-Plus and ET-G groups before antivenom treatment. It had
ceased within 32 minutes of starting antivenom treatment in all
patients and did not recur in any case. Only one patient required
blood transfusion after his PCV fell to 17%. Local necrosis was not
evident on admission but 7/194 of ET-Plus-treated patients (3.6%)
and 15/206 of ET-G-treated patients (7.3%) developed necrosis
during their hospital admission [Table 3; RR 0.50 one-sided 95%
CI upper limit 1.03; P=0.08]. Surface area of necrotic skin, and
numbers requiring surgical debridement, skin grafting or
amputation were not significantly different.
ET-Plus also caused severe reactions (bronchospasm/GI
symptoms) on significantly more occasions than did ET-G [21/
194 (10.8%) and 11/206 (5.3%) respectively [RR 2.03 one-sided
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mild (pruritus or urticaria only).
Duration of hospitalization was similar in the two groups
(Table 3).
Discussion
Effectiveness
In more than three quarters of the patients in this trial, blood
coagulability was restored within 6 hr of the initial doses of ET-
Plus and ET-G antivenoms, with no recurrence of incoagulability
12, 18, 24 or 48 hr later. The initial doses had been derived from
preclinical test potency and confirmed by preliminary open dose-
finding and safety studies [35]. Restoration of blood coagulability
has been used as a surrogate marker of antivenom effectiveness in
many clinical studies of viper-bite-induced consumption coagu-
lopathy [3-6,8-17]. In this respect, ET-Plus not only proved non-
inferior to ET-G, but showed weak evidence of superiority (RR
1.10 one-sided 95% CI lower limit 1.01; P=0.05). The low
incidence of recurrent coagulopathy (7 after ET-Plus, 17 after
ET-G see Table 3) contrasted with the frequency of this
phenomenon when Fab fragment antivenoms are used. This is
Figure 1. Flow of participants through the trial.
doi:10.1371/journal.pntd.0000767.g001
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Characteristic EchiTAb Plus-ICP EchiTAb G
(n=194) (n=206)
Age (yrs) - mean (SD) 25.4 (12.0) 25.7 (13.1)
[range] [6–60] [7–60]
aged ,14 yrs 29 (14.9%) 39 (18.9%)
Male 138 (71.1%) 137 (66.5%)
Weight (Kg)
Mean (SD) 52.1 (14.0) 52.3 (15.4)
Median (range) 54.0 (14.0–86.7) 55.0 (19.0–92.5)
Missing 0 2 (1.0%)
Height (m)
Mean (SD) 1.59 (0.16) 1.57 (0.16)
Median (range) 1.60 (1.09–1.90) 1.60 (1.08–1.88)
Missing 0 1 (0.5%)
Dead Echis ocellatus brought 83 (42.8%) 77 (37.4%)
Missing 111 (57.2%) 129 (62.6%)
Occupation
farmers 49 (25.3%) 69 (33.5%)
cattle rearers 26 (13.4%) 27 (13.1%)
other 119 (61.1%) 110 (53.4%)
Circumstance of bite
working 27 (14.3%) 29 (14.2%)
walking 64 (33.9%) 84 (41.2%)
other 98 (51.9%) 91 (44.6%)
Missing 5 (2.6%) 2 (1.0%)
Time from bite to admission (hours)Median 8.7 9.3
(IQR) (4.3–17.5) (4.7–16.6)
(entire range) (0.20–70.32) (0.10–72.00)
Site of bite
lower limb 143 (73.7%) 155 (75.2%)
upper limb 49 (25.3%) 48 (23.3%)
other 2 (1.0%) 3 (1.5%)
Local presenting features
any swelling 193 (99.5%) 206 (100.0%)
severe swelling* 113 (58.2%) 130 (63.1%)
blistering 11 (5.7%) 11 (5.3%)
local bleeding 126 (64.9%) 139 (67.5%)
painful regional lymph nodes 124 (63.9%) 148 (71.8%)
bruising 2 (1.0%) 2 (1.0%)
Systemic presenting features
vomiting 63 (32.5%) 66 (32.0%)
bleeding gums 41 (21.1%) 49 (23.8%)
epistaxis 9 (4.6%) 5 (2.4%)
haematuria 7 (3.6%) 12 (5.8%)
haematemesis 7 (3.6%) 10 (4.9%)
haemoptysis 4( 2 . 1 % ) 0
melaena 3 (1.6%) 3 (1.5%)
Spontaneous systemic bleeding 71 (36.6%) 79 (38.3%)
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antivenoms [8,30,36]. The effectiveness of ET-Plus and ET-G
compares favourably with the results published for a new
candidate equine F(ab’)2 antivenom with specificity for E. ocellatus
venom, African AntivipmynH (Laboratorios Silanes, Mexico)
[12,37]. Among 289 patients recruited to an open multi-centre
trial in Benin, West Africa, 79% had incoagulable blood
suggesting systemic envenoming by E. ocellatus and 3% died.
After treatment with an initial dose of 2 vials of African
AntivipmynH (based on results of pre-clinical rodent assays) that
was repeated according to clinical criteria, 18% of the patients
still had incoagulable blood 24 hr after starting treatment and
restoration of blood coagulability was delayed beyond 60 hours in
6% of them [5]. Recurrent coagulopathy occurred in 25% of
their patients compared to 6% in ours. Bleeding was arrested
within 2 hours in 60% and within 24 hours in 80%, compared to
an upper limit of 32 minutes in our patients. Surprisingly, results
of a subsequent preliminary dose finding study of African
AntivipmynH in 129 patients suggested that reducing the average
total dosage of antivenom from 3.81 to 2.21 vials per patient did
not reduce the efficacy of the treatment, implying a rather flat
dose-response curve [38].
Safety
ET-Plus caused one or more reactions in 50/194 (25.8%)
patients compared to 39/206 (18.9%) for ET-G. The incidence of
these early antivenom reactions should be compared to 15.2% and
57% with 10 ml and 20 ml of the original lyophilised EchiTAb-
Fab [8] and 17% with SAVP Echis antivenom [9]. In the trial of
African AntivipmynH, ‘‘unexpected events’’ were observed in 19%
of patients, including shock, dyspnoea, cough and angioedema [5].
In our trial, bronchospasm or gastrointestinal symptoms, classified
as severe reactions, were more frequent with ET-Plus (10.8%
compared to 5.3%) probably reflecting the three times greater
dose of IgG protein administered as the initial and subsequent
doses of this antivenom (1.20 g) compared to ET-G (0.37 g) [35]
and also possibly the greater dilution of ET-G (1:4) compared to
ET-Plus (3:4) antivenom in the 40 ml injectate administered to all
the patients. Only one quarter of the patients reported for follow
up 2 weeks after the bite and among these, late serum sickness
reactions were reported by 10.2% who had received ET-Plus and
5.2% ET-G (Table 2). However, these incidences may have been
exaggerated if those with symptoms were more likely to return to
the hospital.
There were no fatalities among the study patients but without a
placebo control group the prognosis of untreated E. ocellatus
victims fulfilling our entry criteria is uncertain. However, the
danger of E. ocellatus envenoming is shown by the fact that, at
Kaltungo Hospital, 9 E. ocellatus victims died after the supply of
antivenom faltered in June 2009.
Antivenoms for Africa
Throughout the African savanna north of the equator, the
overwhelming need is for an antivenom to treat envenoming by
Echis spp. (E. leucogaster, E. jogeri, E. pyramidum and especially E.
ocellatus), the predominant cause of fatal and debilitating snake bite
[1,3,4,6,8,18]. Systemic envenoming by Echis spp. is conveniently
detected by simple tests of whole blood coagulability, such as
20WBCT, allowingthe useof monospecificantivenomssuch as ET-
G or SAVP Echis antivenom even when the causative snake cannot
be identified directly. However, ET-Plus is raised against venoms of
two other medically important species complexes in the same
Table 2. Summary of primary and secondary (safety) outcomes plus comparative statistics (intention-to-treat population).
Outcome EchiTAb Plus-ICP EchiTAb G Relative Risk
1 P-value2
(n=194) (n=206) (one-sided 95% CI)
PRIMARY OUTCOME
Permanent restoration of blood coagulability
(20WBCT) 6 hr after 1
st dose of antivenom
161 (83.0%) 156 (75.7%) 1.10 (Lower limit 1.01) 0.05
SECONDARY (SAFETY) OUTCOMES
Early anaphylactic-type reactions
Patients experiencing $1 reaction 50 (25.8%) 39 (18.9%) 1.36 (Upper limit 1.86) 0.06
Early pyrogenic reactions 0 0 inestimable N/A
Late serum sickness type reactions 5/49 (10.2%) 3/58 (5.2%) 1.97 (Upper limit 6.28) 0.27
1Lower limit appropriate when comparing antivenom effectiveness (positive events); upper limit appropriate when comparing safety (negative events).
2One-sided P-values calculated using Fisher’s Exact test.
doi:10.1371/journal.pntd.0000767.t002
Table 1. Cont.
Characteristic EchiTAb Plus-ICP EchiTAb G
(n=194) (n=206)
shock/low BP (systolic ,90 mmHg) 10 (5.2%) 16 (7.8%)
SD – standard deviation.
IQR- interquartile range (25
th -7 5
th percentile).
*Severe swelling = swelling affecting more than half of the limb.
All patients complained of pain; none was in shock or had an un-recordable blood pressure.
doi:10.1371/journal.pntd.0000767.t001
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broadening its potential usefulness. Cross-neutralisation of venoms
of several Echis, Bitis and Naja spp. by ET-Plus has been
demonstrated in rodents [34] but its efficacy against envenoming
by these species must be addressed by future clinical studies.
Clinical testing of antivenoms
Traditionally, the clinical use of antivenoms, a neglected class of
biological drugs, has been based almost entirely on results of
laboratory tests in animals. In future, however, WHO [28] will
strongly encourage the procedure carried out in the present
programme: preclinical tests and preliminary dose-finding and
safety studies [35] followed by formal Phase III clinical trials. In
the present study, conventional pre-clinical rodent ED50 assays
reliably predicted clinical effectiveness of ET-Plus and ET-G.
Surely such tests should become a minimal requirement before an
antivenom is selected for clinical use in a particular country and to
prevent the unscrupulous marketing of geographically inappro-
priate antivenoms [24]. This is now the policy of the Nigerian
regulatory agency NAFDAC. In the case of E. ocellatus bites, in
which coagulopathy is a clinically relevant and objectively
measurable effect of envenoming, results of our preliminary Phase
I dose-finding and safety tests, using a novel 3+3 dose escalation
protocol, were confirmed by the outcome of the Phase III RCT.
This protocol should be considered in similar situations as a
substitute for conventional Phase I studies that many consider
unethical for antivenom testing [39].
Table 3. Ancillary clinical outcomes.
Outcome EchiTAb Plus-ICP EchiTAb G Relative Risk
1 P-value2
(n=194) (n=206) (one-sided 95% CI)
Permanent restoration of blood
coagulability (20WBCT) 24 hr after 1st
dose, having received total of 1-4 doses
184 (94.8%) 192 (93.2%) 1.02 (Lower limit 0.98) 0.32
Recurrent blood incoagulability after
initial restoration of blood coagulability
7 (3.6%) 17 (8.3%) 0.44 (Upper limit 0.90) 0.04
Patients requiring rescue treatment
because their blood was incoagulable
24 hr after 1
st dose
2 (1.0%) 2 (0.97%) 1.06 (Upper limit 5.46) 0.67
Antivenom reactions
Early anaphylactic-type reactions to:
1
st dose of antivenom 48 (24.7%) 36 (17.5%) 1.42 (Upper limit 1.96) 0.05
2
nd dose 4/33 (12.1%) 4/50 (8.0%)
3
rd dose 0/7 (0.0%) 0/9 (0.0%)
4
th dose 1/3 (33.3%) 0/4 (0.0%)
% total early reactions/total antivenom
doses administered 53/238 (22.3%) 40/270 (14.8%)
% severe early reactions/total antivenom
doses administered 21/238 (8.8%) 11/270 (4.1%)
Severity of antivenom reactions:
Total patients experiencing reactions 50 (25.8%) 39 (18.9%) 1.36 (Upper limit 1.86) 0.06
Patients experiencing pruritis and/or
urticaria only (‘‘Mild’’)
32 (16.5%) 29 (14.1%) 1.17 (Upper limit 1.73) 0.3
Patients experiencing bronchospasm or
gastro-intestinal symptoms (‘‘Severe’’)
21 (10.8%) 11 (5.3%) 2.03 (Upper limit 3.66) 0.03
Packed cell volume (%) number
,30% on discharge from hospital 13 (6.7%) 15 (7.3%) 0.92 (Upper limit 1.68) 0.49
Necrosis 7 (3.6%) 15 (7.3%) 0.50 (Upper limit 1.03) 0.08
Fatalities 0 0 unestimable N/A
Length of hospital stay (hours)
median (interquartile range) 120 (96–120) 120 (96–144) Zero (Upper limit zero) 0.2
1Lower limit provided when comparing antivenom effectiveness (positive events); upper limit provided when comparing safety (negative events).
2One-sided P-values calculated using Fisher’s Exact test (apart from Length of hospital stay).
doi:10.1371/journal.pntd.0000767.t003
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Comparison of initial doses of 3 vials of ET-Plus (a new
antivenom) with 1 vial of ET-G (whose clinical efficacy had been
established through pre-trial use and has been the standard of care
since 2005) demonstrated that, at this dose, ET-Plus was slightly
more effective in correcting haemostatic effects of E. ocellatus
envenoming in Nigeria. ET-Plus has the potential advantage of a
broader spectrum of activity. However, 1 vial of ET-G was slightly
safer. Both antivenoms are recommended for treating E. ocellatus
envenoming in Nigeria.
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